Aclaris Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>AT</div>
ACRS -- USA Stock  

USD 2.54  0.15  6.28%

Even with relatively unfluctuating basic indicators, Aclaris Therapeutics may actually be approaching a critical reversion point that can send shares even higher in September 2020. Aclaris Therapeutics probability of distress is over 54 percent. Will retail investors continue to be optimistic, or should we expect a sell-off in September?
Published over a month ago
View all stories for Aclaris Therapeutics | View All Stories
Does Aclaris Therapeutics (NASDAQ:ACRS) have invariable basic indicators based on the latest spike?
Aclaris Therapeutics is very risky given 1 month investment horizon. Aclaris Therapeutics secures Sharpe Ratio (or Efficiency) of 0.2, which signifies that the company had 0.2% of return per unit of risk over the last month. Our standpoint towards foreseeing the risk of a stock is to use both market data as well as company specific technical data. We were able to interpolate data for twenty-one different technical indicators, which can help you to evaluate if expected returns of 1.17% are justified by taking the suggested risk. Use Aclaris Therapeutics Risk Adjusted Performance of 0.3074, mean deviation of 4.4, and Downside Deviation of 4.59 to evaluate company specific risk that cannot be diversified away.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Aclaris Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Aclaris Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may use each financial statement separately, they are all related. The changes in Aclaris Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aclaris Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of Aclaris Therapeutics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Aclaris Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Aclaris Therapeutics shares is the value that is considered the true value of the share. If the intrinsic value Aclaris is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Aclaris Therapeutics. Please read more on our fundamental analysis page.

What is Aclaris Asset Breakdown?

Aclaris Therapeutics reports assets on its Balance Sheet. It represents the amount of Aclaris resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Aclaris volatility, please check the breakdown of all its fundamentals

Are Aclaris Therapeutics Earnings Expected to grow?

The future earnings power of Aclaris Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Aclaris Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Aclaris Therapeutics stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Aclaris expected earnings.

Aclaris Therapeutics Gross Profit

Aclaris Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Aclaris Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Aclaris Therapeutics Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

A Deeper Perspective

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Aclaris Therapeutics is not uncomon. Institutional investors typically avoid acquiring a high percentage of Aclaris Therapeutics stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Aclaris is distributed among investors.

Ownership Allocation

Aclaris Therapeutics holds a total of fourty-two million seven hundred twenty thousand outstanding shares. The majority of Aclaris Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Aclaris Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Aclaris Therapeutics. Please pay attention to any change in the institutional holdings of Aclaris Therapeutics as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors
5.18%
Insiders
10.01%
Institutions
84.81%
Retail Investors5.18
Insiders10.01
Institutions84.81

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aclaris Therapeutics has an asset utilization ratio of 5.88 percent. This connotes that the company is making $0.0588 for each dollar of assets. An increasing asset utilization means that Aclaris Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
112.1 M
Current Assets112.13 Million83.43
Assets Non Current14.88 Million11.07
Goodwill7.39 Million5.5

Another 3 percent spike for Aclaris Therapeutics

The sortino ratio is down to 0.18 as of today. As of the 16th of August 2020, Aclaris Therapeutics shows the Mean Deviation of 4.4, risk adjusted performance of 0.3074, and Downside Deviation of 4.59. Aclaris Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Aclaris Therapeutics, which can be compared to its rivals. Please confirm Aclaris Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Aclaris Therapeutics is priced correctly, providing market reflects its regular price of 2.46 per share. Please also double-check Aclaris Therapeutics total risk alpha, which is currently at 0.0636 to validate the company can sustain itself at a future point.

Our Final Perspective on Aclaris Therapeutics

While few other entities under the biotechnology industry are still a bit expensive, Aclaris Therapeutics may offer a potential longer-term growth to retail investors. Taking everything into account, as of the 16th of August 2020, we believe that at this point, Aclaris Therapeutics is very risky with average odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our latest 30 days 'Buy-vs-Sell' recommendation on the enterprise is Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Aclaris Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com